openPR Logo
Press release

Advanced Recurrent Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

02-17-2025 11:38 PM CET | Health & Medicine

Press release from: ABNewswire

Advanced Recurrent Ovarian Cancer Clinical Trials and Studies:

DelveInsight's, "Advanced Recurrent Ovarian Cancer Pipeline Insight" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Recurrent Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Advanced Recurrent Ovarian Cancer Pipeline Report to explore emerging therapies, key Advanced Recurrent Ovarian Cancer Companies, and future Advanced Recurrent Ovarian Cancer treatment landscapes @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

* In February 2025:- Mayo Clinic - This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States.
* DelveInsight's Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
* The leading Advanced Recurrent Ovarian Cancer Companies such as IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.
* Promising Advanced Recurrent Ovarian Cancer Therapies such as OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.

Discover how the Advanced Recurrent Ovarian Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Advanced Recurrent Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Recurrent Ovarian Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Recurrent Ovarian Cancer Emerging Drugs

* Maveropepimut S: IMV

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV's new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S' ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients' quality of life.

* ELU 001: Elucida Oncology

ELU001 is a novel, first-in-class, new molecular entity described as a C'Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C'Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001's high avidity is believed to promote internalization into FR overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

* A166: Klus Pharma

A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

The Advanced Recurrent Ovarian Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Recurrent Ovarian Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Recurrent Ovarian Cancer Treatment.
* Advanced Recurrent Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Advanced Recurrent Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Recurrent Ovarian Cancer market.

Get a detailed analysis of the latest innovations in the Advanced Recurrent Ovarian Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Advanced Recurrent Ovarian Cancer Unmet Needs [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Recurrent Ovarian Cancer Companies

IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming Advanced Recurrent Ovarian Cancer Therapies and key Advanced Recurrent Ovarian Cancer Developments @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

* Coverage- Global
* Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.
* Advanced Recurrent Ovarian Cancer Therapies- OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin , and others.
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Advanced Recurrent Ovarian Cancer drug development? Find out in DelveInsight's exclusive Advanced Recurrent Ovarian Cancer Pipeline Report-access it now! @ Advanced Recurrent Ovarian Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced Recurrent Ovarian Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Recurrent Ovarian Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Maveropepimut S: IMV
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Recurrent Ovarian Cancer Key Companies
* Advanced Recurrent Ovarian Cancer Key Products
* Advanced Recurrent Ovarian Cancer- Unmet Needs
* Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
* Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
* Advanced Recurrent Ovarian Cancer Analyst Views
* Advanced Recurrent Ovarian Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-recurrent-ovarian-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advanced Recurrent Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here

News-ID: 3872518 • Views:

More Releases from ABNewswire

Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 Billion by 2030 | Arizton
Global Sound Reinforcement Market Set to Grow at 4.28% CAGR, Reaching USD 38.58 …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030. The global sound reinforcement market [https://www.arizton.com/market-reports/sound-reinforcement-market-size-growth] is projected to expand from USD 30 billion in 2024 to USD 38.58 billion by 2030, growing at a steady 4.28% CAGR, according to Arizton. This growth is being driven by rising demand for high-quality audio solutions across live events and entertainment venues. Advances in audio technology have significantly enhanced
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Investors
Gelt Raises $13M Series A to Expand AI-Powered Tax Solutions for Real Estate Inv …
Miami, FL - September 30, 2025 - Gelt [https://www.joingelt.com/], the first AI-native tax firm for investors and the Top 1% in the U.S., today announced it has raised $13 million in Series A [https://www.businesswire.com/news/home/20250930325477/en/Gelt-the-First-AI-Native-Tax-Firm-Raises-%2413M-in-Series-A-Funding-to-Transform-Tax-Strategy-Into-Year-Round-Wealth-Optimization], bringing its total funding to $21.2 million. Global investors, Zvi Limon of the Rimon Group, Vintage Investment Partners, and TLV Partners led the funding. As part of the launch, Yoram Tietz, former Managing Partner at EY
Applications of 5-50mm security camera lens
Applications of 5-50mm security camera lens
The application scenarios of 5-50 mm surveillance lenses are primarily categorized according to the variations in field of view resulting from changes in focal length. The specific applications are as follows: 1. Wide-angle range (5-12 mm) Panoramic monitoring for confined spaces A focal length of 5-8 mm (with a field of view of 60 degrees -90 degrees ) is suitable for enclosed small areas within 5 times 5 meters, such as elevator
Daniel Smart Manufacturing Empowers Riders with their New Custom Builder Feature on Leather Jackets & Vests
Daniel Smart Manufacturing Empowers Riders with their New Custom Builder Feature …
A leather jacket [https://danielsmartmfg.com/collections/mens-leather-motorcycle-jackets] for a rider is an essential part of their ride, and it makes them feel incomplete without it whenever they hit the road. If you are a biker, you must know what it means. Now imagine you can design your leather jacket your way, which may further enhance your experience on the road. Well, Daniel Smart, a renowned brand in the leather jacket industry, is now

All 5 Releases


More Releases for Ovarian

Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth. Browse
Ovarian Cancer Drugs Market Report 2020-2030
Forecasts by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) Plus Analysis of Leading Companies Download free sample pages: https://www.visiongain.com/report/ovarian-cancer-drugs-market-report-2020-2030/ Ovarian Cancer Drugs Market- our new study reveals trends, R&D progress, and predicted revenues Where the Ovarian Cancer Drugs is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there. Discover
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in